Sareum reports progress across pipeline
9th Dec 2025 13:44
(Sharecast News) - Sareum updated investors on progress across its pipeline ahead of its annual general meeting on Tuesday, highlighting continued advances in its lead autoimmune candidate SDC-1801 and strengthening commercial positioning for its cancer assets SDC-1802 and SRA737.
Read moreSareum halts toxicology study after control-group safety findings
10th Oct 2025 07:45
(Sharecast News) - Clinical-stage biotechnology firm Sareum said on Friday that it has discontinued its 16-week pre-clinical toxicology study for autoimmune and cancer candidate SDC-1801 after safety issues were flagged by a third-party provider.
Read moreSareum starts toxicology studies for lead inhibitor
29th May 2025 14:40
(Sharecast News) - Sareum announced the start of a programme of toxicology studies on Thursday, for its lead TYK2/JAK1 inhibitor - SDC-1801 - marking a key step toward phase two clinical development.
Read moreSareum shares drop on product licence termination
31st Dec 2024 07:49
(Sharecast News) - Autoimmune disease and cancer treatment developer Sareum has revealed that the commercial licence of its jointly developed SRA737 product has been terminated by a biopharma company in the US.
Read moreSareum shares rise on China patent allowance
16th Sep 2024 11:29
(Sharecast News) - Cambridge-based biotechnology firm Sareum Holdings announced on Monday that it has received a notice of allowance from the China National Intellectual Property Administration for its patent application concerning crystalline forms of SDC-1801.
Read moreSareum announces positive results from kinase inhibitor trial
1st Jul 2024 11:23
(Sharecast News) - Sareum Holdings announced positive topline results from its phase 1a clinical trial of SDC-1801, a dual TYK2/JAK1 kinase inhibitor under development for treating autoimmune diseases.
Read moreSareum allowed European patent for primary kinase inhibitor asset
15th Mar 2024 13:11
(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.
Read moreSareum reports positive progress in psoriasis programme
15th Feb 2024 13:22
(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.
Read moreSareum shares jump on cancer drug licensing deal
2nd Jan 2024 13:54
(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.
Read moreSareum secures Japan patent for kinase inhibitor asset
3rd Nov 2023 13:59
(Sharecast News) - Biotechnology firm Sareum announced on Friday that it has received a notice of allowance from the Japan Patent Office for a patent associated with SDC-1801, its primary TYK2/JAK1 kinase inhibitor.
Read moreSareum losses widen as clinical trials continue
9th Oct 2023 15:06
(Sharecast News) - Biotechnology company Sareum Holdings reported a loss of £3.2m after tax in its final results on Monday, widening from last year's £2.2m due to heightened expenses from initiating clinical studies with SDC-1801, despite aligning with market anticipations.
Read moreDirector dealings: Blackbird, Sareum insiders pick up shares
6th Sep 2023 14:35
(Sharecast News) - Blackbird found itself with a number of entries on the list of director buys on Wednesday, after a number of insiders and associates bought shares.
Read moreSareum granted new patents in China, US
26th Jun 2023 10:54
(Sharecast News) - Clinical-stage biotechnology developer Sareum announced the granting of patents for its lead kinase inhibitors in China and the United States on Monday.
Read moreSareum gets approval for phase one psoriasis studies in Australia
5th May 2023 15:53
(Sharecast News) - Biotechnology developer Sareum Holdings announced on Friday that it has been granted approval by Australia's Therapeutic Goods Administration (TGA) to conduct phase one clinical studies on SDC-1801.
Read moreSareum looks at options as GSK division returns cancer drug candidate
6th Mar 2023 16:16
(Sharecast News) - Biotechnology developer Sareum announced on Monday that GSK subsidiary Sierra Oncology has returned clinical study reports and associated documents related to 'SRA737' to Sareum's co-development partner, the CRT Pioneer Fund.
Read more